BRIEF published on 11/05/2025 at 18:01, 11 months 25 days ago Christian Mias Appointed as New CEO of SCHOTT Pharma CEO Appointment SCHOTT Pharma Leadership Change Christian Mias Andreas Reisse
PRESS RELEASE published on 11/05/2025 at 17:56, 11 months 25 days ago EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: Christian Mias to succeed Andreas Reisse as CEO SCHOTT Pharma AG & Co. KGaA appoints Christian Mias as CEO to succeed Andreas Reisse, effective May 1, 2026. Inside information disclosed. Press release via EQS News Inside Information CEO Appointment SCHOTT Pharma EQS News Christian Mias
BRIEF published on 08/12/2025 at 07:05, 1 year 2 months ago SCHOTT Pharma Reports Steady Q3 2025 Results Innovation SCHOTT Pharma High-value Solutions Drug Containment Q3 2025 Results
PRESS RELEASE published on 08/12/2025 at 07:00, 1 year 2 months ago SCHOTT Pharma delivers solid final third-quarter results SCHOTT Pharma reports solid Q3 2025 results with 1% revenue growth, 32.4% EBITDA margin, and strategic innovations Revenue Growth EBITDA Margin SCHOTT Pharma Innovations Q3 2025 Results
BRIEF published on 08/05/2025 at 10:00, 1 year 2 months ago SCHOTT Pharma's Q3 2025 Highlights and FY 2025 Outlook Revenue Growth EBITDA Margin Financial Outlook Q3 2025 High Value Solutions
BRIEF published on 08/05/2025 at 09:58, 1 year 2 months ago SCHOTT Pharma Updates FY 2025 Revenue and EBITDA Guidance Financial Results Revenue Growth EBITDA Margin SCHOTT Pharma FY 2025 Guidance
PRESS RELEASE published on 08/05/2025 at 09:55, 1 year 2 months ago SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance SCHOTT Pharma reports Q3 2025 revenues up 3% yoy at EUR 256m and gives FY 2025 guidance with EBITDA expected to be around 28.0%. Full financial results to be published on August 12, 2025 Revenues EBITDA SCHOTT Pharma Q3 2025 FY 2025 Guidance
PRESS RELEASE published on 08/05/2025 at 09:53, 1 year 2 months ago EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin SCHOTT Pharma AG & Co. KGaA specifies FY 2025 guidance for revenue growth and EBITDA margin, expecting 6.0% organic revenue growth and 28.0% EBITDA margin Revenue Growth EBITDA Margin SCHOTT Pharma Guidance FY 2025
BRIEF published on 06/11/2025 at 08:55, 1 year 4 months ago SCHOTT Pharma Extends CEO Contract and Appoints New CFO Global Expansion CEO Contract Extension Innovative Leadership New CFO Appointment Pharmaceutical Containment
PRESS RELEASE published on 06/11/2025 at 08:50, 1 year 4 months ago SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO SCHOTT Pharma extends CEO's contract Andreas Reisse & appoints Reinhard Mayer as CFO. Strategic personnel changes at SCHOTT Pharma AG & Co. KGaA CFO Appointment SCHOTT Pharma Personnel Changes CEO Contract Reinhard Mayer
Published on 10/30/2026 at 23:35, 1 day 7 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 7 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 12 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 15 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 05:00, 2 hours 19 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 14 hours 44 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 8 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 1 day 8 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 1 day 19 hours ago Capital increase through exercise of subscription rights
